Login Register Cart 0
Systematic Review Article

比较双膦酸盐疗法对骨质疏松症持续性和依从性的疗效：系统综述

卷 22, 期 3, 2022

发表于: 14 April, 2021

页: [274 - 284] 页: 11

弟呕挨: 10.2174/1566524021666210414100227

价格: $65

摘要

目的：骨质疏松症是全世界最普遍的代谢性骨病。本综述旨在比较双膦酸盐治疗对骨质疏松症患者的持久性和依从性的疗效。 方法：根据可用的报告项目进行系统评价。应用 MEDLINE 和 Cochrane 图书馆数据库检索截至 2020 年 1 月的文献。包括所有主要研究，如检查患者对双膦酸盐治疗骨质疏松症的持久性或依从性的前瞻性、回顾性和评论文章。 结果：文献检索共检索到656篇相关已发表报告，其中87篇被纳入。研究了 10、712、176 名骨质疏松症患者的患者持久性，研究了 5、875、718 名患者的患者依从性。对所有研究的双膦酸盐的分析显示，患者持续率的模式几乎相似，因为它在初始处方后随时间下降，但与其他研究的双膦酸盐相比，发现阿仑膦酸盐治疗的持续时间显着更高（p<0.001），而所有其他双膦酸盐（阿仑膦酸盐除外）的持续时间几乎相同（p>0.05）。对患者依替膦酸盐治疗依从性的分析显示，12 个月时药物拥有率 (MRP) 最高，其次是伊班膦酸盐、阿仑膦酸盐、利塞膦酸盐和氯膦酸盐的 MRP。 结论：这是第一个系统评价，比较了双膦酸盐治疗骨质疏松症的患者持久性和依从性的效率。数据显示，阿仑膦酸盐治疗的患者持续时间最长，而依替膦酸盐治疗骨质疏松症的患者依从性最高。

关键词: 双膦酸盐，比较，持久性，依从性，MRP，骨质疏松症

« Previous
[1]
Ensrud KE, Crandall CJ. Osteoporosis. Ann Intern Med 2017; 167(3): ITC17-32.
[http://dx.doi.org/10.7326/AITC201708010] [PMID: 28761958]
[2]
Link TM, Kazakia G. Update on imaging-based measurement of bone mineral density and quality. Curr Rheumatol Rep 2020; 22(5): 13.
[http://dx.doi.org/10.1007/s11926-020-00892-w] [PMID: 32270332]
[3]
Miller PD. Management of severe osteoporosis. Expert Opin Pharmacother 2016; 17(4): 473-88.
[http://dx.doi.org/10.1517/14656566.2016.1124856] [PMID: 26605922]
[4]
Kanis JA, Oden A, Johnell O, Jonsson B, de Laet C, Dawson A. The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int 2001; 12(5): 417-27.
[http://dx.doi.org/10.1007/s001980170112] [PMID: 11444092]
[5]
Christensen K, Doblhammer G, Rau R, Vaupel JW. Ageing populations: the challenges ahead. Lancet 2009; 374(9696): 1196-208.
[http://dx.doi.org/10.1016/S0140-6736(09)61460-4] [PMID: 19801098]
[6]
Wright NC, Looker AC, Saag KG, et al. The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine. J Bone Miner Res 2014; 29(11): 2520-6.
[http://dx.doi.org/10.1002/jbmr.2269] [PMID: 24771492]
[7]
Delitala AP, Scuteri A, Doria C. Thyroid hormone diseases and osteoporosis. J Clin Med 2020; 9(4): E1034.
[http://dx.doi.org/10.3390/jcm9041034] [PMID: 32268542]
[8]
Prestwood KM, Pilbeam CC, Raisz LG. Treatment of osteoporosis. Annu Rev Med 1995; 46: 249-56.
[http://dx.doi.org/10.1146/annurev.med.46.1.249] [PMID: 7598461]
[9]
Favus MJ. Bisphosphonates for osteoporosis. N Engl J Med 2010; 363(21): 2027-35.
[http://dx.doi.org/10.1056/NEJMct1004903] [PMID: 21083387]
[10]
Trivedi R, Mithal A, Chattopadhyay N. Anabolics in osteoporosis: the emerging therapeutic tool. Curr Mol Med 2010; 10(1): 14-28.
[http://dx.doi.org/10.2174/156652410791065372] [PMID: 20205677]
[11]
Watts NB. Treatment of osteoporosis with bisphosphonates. Rheum Dis Clin North Am 2001; 27(1): 197-214.
[http://dx.doi.org/10.1016/S0889-857X(05)70194-0] [PMID: 11285996]
[12]
Watts NB, Lewiecki EM, Miller PD, Baim S. National osteoporosis foundation 2008 clinician’s guide to prevention and treatment of osteoporosis and the world health organization fracture risk assessment tool (FRAX): what they mean to the bone densitometrist and bone technologist. J Clin Densitom 2008; 11(4): 473-7.
[http://dx.doi.org/10.1016/j.jocd.2008.04.003] [PMID: 18562228]
[13]
Grey A, Reid IR. Differences between the bisphosphonates for the prevention and treatment of osteoporosis. Ther Clin Risk Manag 2006; 2(1): 77-86.
[PMID: 18360583]
[14]
Abrahamsen B. Adverse effects of bisphosphonates. Calcif Tissue Int 2010; 86(6): 421-35.
[http://dx.doi.org/10.1007/s00223-010-9364-1] [PMID: 20407762]
[15]
Rosella D, Papi P, Giardino R, Cicalini E, Piccoli L, Pompa G. Medication-related osteonecrosis of the jaw: Clinical and practical guidelines. J Int Soc Prev Community Dent 2016; 6(2): 97-104.
[http://dx.doi.org/10.4103/2231-0762.178742] [PMID: 27114946]
[16]
Hiligsmann M, Rabenda V, Bruyère O, Reginster JY. The clinical and economic burden of non-adherence with oral bisphosphonates in osteoporotic patients. Health Policy 2010; 96(2): 170-7.
[http://dx.doi.org/10.1016/j.healthpol.2010.01.014] [PMID: 20153543]
[17]
Park JH, Park EK, Koo DW, et al. Compliance and persistence with oral bisphosphonates for the treatment of osteoporosis in female patients with rheumatoid arthritis. BMC Musculoskelet Disord 2017; 18(1): 152.
[http://dx.doi.org/10.1186/s12891-017-1514-4] [PMID: 28399834]
[18]
Imaz I, Zegarra P, González-Enríquez J, Rubio B, Alcazar R, Amate JM. Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis. Osteoporos Int 2010; 21(11): 1943-51.
[http://dx.doi.org/10.1007/s00198-009-1134-4] [PMID: 19967338]
[19]
Fatoye F, Smith P, Gebrye T, Yeowell G. Real-world persistence and adherence with oral bisphosphonates for osteoporosis: a systematic review. BMJ Open 2019; 9(4): e027049.
[http://dx.doi.org/10.1136/bmjopen-2018-027049] [PMID: 30987990]
[20]
Cramer JA, Gold DT, Silverman SL, Lewiecki EM. A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 2007; 18(8): 1023-31.
[http://dx.doi.org/10.1007/s00198-006-0322-8] [PMID: 17308956]
[21]
Moher D, Liberati A, Tetzlaff J, Altman DG. PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6(7): e1000097.
[http://dx.doi.org/10.1371/journal.pmed.1000097] [PMID: 19621072]
[22]
Hughes D, Cowell W, Koncz T, Cramer J. International society for pharmacoeconomics & outcomes research economics of medication compliance working group. Methods for integrating medication compliance and persistence in pharmacoeconomic evaluations. Value Health 2007; 10(6): 498-509.
[http://dx.doi.org/10.1111/j.1524-4733.2007.00205.x] [PMID: 17970932]
[23]
Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010; 25(9): 603-5.
[http://dx.doi.org/10.1007/s10654-010-9491-z] [PMID: 20652370]
[24]
Cramer JA, Silverman SL, Gold DT. Methodological considerations in using claims databases to evaluate persistence with bisphosphonates for osteoporosis. Curr Med Res Opin 2007; 23(10): 2369-77.
[http://dx.doi.org/10.1185/030079907X226311] [PMID: 17711617]
[25]
Burden AM, Paterson JM, Solomon DH, Mamdani M, Juurlink DN, Cadarette SM. Bisphosphonate prescribing, persistence and cumulative exposure in Ontario, Canada. Osteoporos Int 2012; 23(3): 1075-82.
[http://dx.doi.org/10.1007/s00198-011-1645-7] [PMID: 21604008]
[26]
Burden AM, Paterson JM, Gruneir A, Cadarette SM. Adherence to osteoporosis pharmacotherapy is underestimated using days supply values in electronic pharmacy claims data. Pharmacoepidemiol Drug Saf 2015; 24(1): 67-74.
[http://dx.doi.org/10.1002/pds.3718] [PMID: 25331490]
[27]
Carbonell-Abella C, Pages-Castella A, Javaid MK, et al. Early (1-year) discontinuation of different anti-osteoporosis medications compared: a population-based cohort study. Calcif Tissue Int 2015; 97(6): 535-41.
[http://dx.doi.org/10.1007/s00223-015-0040-3] [PMID: 26202819]
[28]
Ettinger MP, Gallagher R, MacCosbe PE. Medication persistence with weekly versus daily doses of orally administered bisphosphonates. Endocr Pract 2006; 12(5): 522-8.
[http://dx.doi.org/10.4158/EP.12.5.522] [PMID: 17002926]
[29]
Gold DT, Martin BC, Frytak JR, Amonkar MM, Cosman F. A claims database analysis of persistence with alendronate therapy and fracture risk in post-menopausal women with osteoporosis. Curr Med Res Opin 2007; 23(3): 585-94.
[http://dx.doi.org/10.1185/030079906X167615] [PMID: 17355739]
[30]
Hadji P, Klein S, Häussler B, et al. The bone evaluation study (BEST): patient care and persistence to treatment of osteoporosis in Germany. Int J Clin Pharmacol Ther 2013; 51(11): 868-72.
[http://dx.doi.org/10.5414/CP201931] [PMID: 24040854]
[31]
Hadji P, Ziller V, Kyvernitakis J, Schmidt N, Kostev K. Persistence with bisphosphonates in patients with metastatic breast cancer: a retrospective database analysis. J Cancer Res Clin Oncol 2013; 139(7): 1149-55.
[http://dx.doi.org/10.1007/s00432-013-1427-z] [PMID: 23552873]
[32]
Ideguchi H, Ohno S, Hattori H, Ishigatsubo Y. Persistence with bisphosphonate therapy including treatment courses with multiple sequential bisphosphonates in the real world. Osteoporos Int 2007; 18(10): 1421-7.
[http://dx.doi.org/10.1007/s00198-007-0406-0] [PMID: 17577595]
[33]
Iolascon G, Gimigliano F, Orlando V, Capaldo A, Di Somma C, Menditto E. Osteoporosis drugs in real-world clinical practice: an analysis of persistence. Aging Clin Exp Res 2013; 25(Suppl. 1): S137-41.
[http://dx.doi.org/10.1007/s40520-013-0127-5] [PMID: 24046038]
[34]
Jones TJ, Petrella RJ, Crilly R. Determinants of persistence with weekly bisphosphonates in patients with osteoporosis. J Rheumatol 2008; 35(9): 1865-73.
[PMID: 18709688]
[35]
LeBlanc ES, Rosales AG, Balasubramanian A, et al. Risk factors for fracture among current, persistent users of bisphosphonates. Osteoporos Int 2015; 26(2): 713-25.
[http://dx.doi.org/10.1007/s00198-014-2941-9] [PMID: 25354654]
[36]
Li L, Roddam A, Gitlin M, et al. Persistence with osteoporosis medications among postmenopausal women in the UK General Practice Research Database. Menopause 2012; 19(1): 33-40.
[http://dx.doi.org/10.1097/gme.0b013e318221bacd] [PMID: 21926926]
[37]
Penning-van Beest FJ, Goettsch WG, Erkens JA, Herings RM. Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis. Clin Ther 2006; 28(2): 236-42.
[http://dx.doi.org/10.1016/j.clinthera.2006.01.002] [PMID: 16678644]
[38]
Roerholt C, Eiken P, Abrahamsen B. Initiation of anti-osteoporotic therapy in patients with recent fractures: a nationwide analysis of prescription rates and persistence. Osteoporos Int 2009; 20(2): 299-307.
[http://dx.doi.org/10.1007/s00198-008-0651-x] [PMID: 18551241]
[39]
Sheehy O, Kindundu CM, Barbeau M, LeLorier J. Differences in persistence among different weekly oral bisphosphonate medications. Osteoporos Int 2009; 20(8): 1369-76.
[http://dx.doi.org/10.1007/s00198-008-0795-8] [PMID: 19020921]
[40]
Ström O, Landfeldt E. The association between automatic generic substitution and treatment persistence with oral bisphosphonates. Osteoporos Int 2012; 23(8): 2201-9.
[http://dx.doi.org/10.1007/s00198-011-1850-4] [PMID: 22120909]
[41]
van Boven JF, de Boer PT, Postma MJ, et al. Persistence with osteoporosis medication among newly-treated osteoporotic patients. J Bone Miner Metab 2013; 31: 562-70.
[42]
van den Boogaard CH, Breekveldt-Postma NS, Borggreve SE, Goettsch WG, Herings RM. Persistent bisphosphonate use and the risk of osteoporotic fractures in clinical practice: a database analysis study. Curr Med Res Opin 2006; 22(9): 1757-64.
[http://dx.doi.org/10.1185/030079906X132370] [PMID: 16968579]
[43]
Weiss TW, Henderson SC, McHorney CA, Cramer JA. Persistence across weekly and monthly bisphosphonates: analysis of US retail pharmacy prescription refills. Curr Med Res Opin 2007; 23(9): 2193-203.
[http://dx.doi.org/10.1185/030079907X226069] [PMID: 17686228]
[44]
Abrahamsen B. Are long-term bisphosphonate users a reality? Dose years for current bisphosphonate users assessed using the danish national prescription database. Osteoporos Int 2013; 24(1): 369-72.
[http://dx.doi.org/10.1007/s00198-012-1994-x] [PMID: 22572963]
[45]
Curtis JR, Westfall AO, Cheng H, Delzell E, Saag KG. Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday. Osteoporos Int 2008; 19(11): 1613-20.
[http://dx.doi.org/10.1007/s00198-008-0604-4] [PMID: 18483689]
[46]
Lo JC, Pressman AR, Omar MA, Ettinger B. Persistence with weekly alendronate therapy among postmenopausal women. Osteoporos Int 2006; 17(6): 922-8.
[http://dx.doi.org/10.1007/s00198-006-0085-2] [PMID: 16609824]
[47]
Penning-van Beest FJ, Erkens JA, Olson M, Herings RM. Determinants of non-compliance with bisphosphonates in women with postmenopausal osteoporosis. Curr Med Res Opin 2008; 24(5): 1337-44.
[http://dx.doi.org/10.1185/030079908X297358] [PMID: 18380910]
[48]
Fardellone P, Lello S, Cano A, et al. Real-world Adherence and Persistence with Bisphosphonate Therapy in Postmenopausal Women: A Systematic Review. Clin Ther 2019; 41(8): 1576-88.
[http://dx.doi.org/10.1016/j.clinthera.2019.05.001] [PMID: 31151814]
[49]
Silverman SL, Gold DT, Cramer JA. Reduced fracture rates observed only in patients with proper persistence and compliance with bisphosphonate therapies. South Med J 2007; 100(12): 1214-8.
[http://dx.doi.org/10.1097/SMJ.0b013e31815a9685] [PMID: 18090964]
[50]
Brankin E, Walker M, Lynch N, Aspray T, Lis Y, Cowell W. The impact of dosing frequency on compliance and persistence with bisphosphonates among postmenopausal women in the UK: evidence from three databases. Curr Med Res Opin 2006; 22(7): 1249-56.
[http://dx.doi.org/10.1185/030079906X112688] [PMID: 16834823]
[51]
Cramer JA, Amonkar MM, Hebborn A, Altman R. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 2005; 21(9): 1453-60.
[http://dx.doi.org/10.1185/030079905X61875] [PMID: 16197664]
[52]
Cramer JA, Lynch NO, Gaudin AF, Walker M, Cowell W. The effect of dosing frequency on compliance and persistence with bisphosphonate therapy in postmenopausal women: a comparison of studies in the United States, the United Kingdom, and France. Clin Ther 2006; 28(10): 1686-94.
[http://dx.doi.org/10.1016/j.clinthera.2006.10.013] [PMID: 17157124]
[53]
Downey TW, Foltz SH, Boccuzzi SJ, Omar MA, Kahler KH. Adherence and persistence associated with the pharmacologic treatment of osteoporosis in a managed care setting. South Med J 2006; 99(6): 570-5.
[http://dx.doi.org/10.1097/01.smj.0000221637.90495.66] [PMID: 16800411]
[54]
Gallagher AM, Rietbrock S, Olson M, van Staa TP. Fracture outcomes related to persistence and compliance with oral bisphosphonates. J Bone Miner Res 2008; 23(10): 1569-75.
[http://dx.doi.org/10.1359/jbmr.080510] [PMID: 18505366]
[55]
Gold DT, Safi W, Trinh H. Patient preference and adherence: comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate. Curr Med Res Opin 2006; 22(12): 2383-91.
[http://dx.doi.org/10.1185/030079906X154042] [PMID: 17257452]
[56]
Gold DT, Trinh H, Safi W. Weekly versus monthly drug regimens: 1-year compliance and persistence with bisphosphonate therapy. Curr Med Res Opin 2009; 25(8): 1831-9.
[http://dx.doi.org/10.1185/03007990903035604] [PMID: 19530982]
[57]
Hadji P, Claus V, Ziller V, Intorcia M, Kostev K, Steinle T. GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates. Osteoporos Int 2012; 23(1): 223-31.
[http://dx.doi.org/10.1007/s00198-011-1535-z] [PMID: 21308365]
[58]
Hansen C, Pedersen BD, Konradsen H, Abrahamsen B. Anti-osteoporotic therapy in Denmark--predictors and demographics of poor refill compliance and poor persistence. Osteoporos Int 2013; 24(7): 2079-97.
[http://dx.doi.org/10.1007/s00198-012-2221-5] [PMID: 23179576]
[59]
Höer A, Seidlitz C, Gothe H, et al. Influence on persistence and adherence with oral bisphosphonates on fracture rates in osteoporosis. Patient Prefer Adherence 2009; 3: 25-30.
[PMID: 19936142]
[60]
Kishimoto H, Maehara M. Compliance and persistence with daily, weekly, and monthly bisphosphonates for osteoporosis in Japan: analysis of data from the CISA. Arch Osteoporos 2015; 10: 231.
[http://dx.doi.org/10.1007/s11657-015-0231-6] [PMID: 26297076]
[61]
Lakatos P, Takács I, Marton I, et al. A retrospective longitudinal database study of persistence and compliance with treatment of osteoporosis in hungary. Calcif Tissue Int 2016; 98(3): 215-25.
[http://dx.doi.org/10.1007/s00223-015-0082-6] [PMID: 26686694]
[62]
Netelenbos JC, Geusens PP, Ypma G, Buijs SJ. Adherence and profile of non-persistence in patients treated for osteoporosis--a large-scale, long-term retrospective study in The Netherlands. Osteoporos Int 2011; 22(5): 1537-46.
[http://dx.doi.org/10.1007/s00198-010-1372-5] [PMID: 20838773]
[63]
Rietbrock S, Olson M, van Staa TP. The potential effects on fracture outcomes of improvements in persistence and compliance with bisphosphonates. QJM 2009; 102(1): 35-42.
[http://dx.doi.org/10.1093/qjmed/hcn130] [PMID: 18842684]
[64]
Soong YK, Tsai KS, Huang HY, et al. Risk of refracture associated with compliance and persistence with bisphosphonate therapy in Taiwan. Osteoporos Int 2013; 24(2): 511-21.
[http://dx.doi.org/10.1007/s00198-012-1984-z] [PMID: 22588182]
[65]
Sunyecz JA, Mucha L, Baser O, Barr CE, Amonkar MM. Impact of compliance and persistence with bisphosphonate therapy on health care costs and utilization. Osteoporos Int 2008; 19(10): 1421-9.
[http://dx.doi.org/10.1007/s00198-008-0586-2] [PMID: 18351427]
[66]
Yeaw J, Benner JS, Walt JG, Sian S, Smith DB. Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm 2009; 15(9): 728-40.
[http://dx.doi.org/10.18553/jmcp.2009.15.9.728] [PMID: 19954264]
[67]
Ziller V, Kostev K, Kyvernitakis I, Boeckhoff J, Hadji P. Persistence and compliance of medications used in the treatment of osteoporosis--analysis using a large scale, representative, longitudinal German database. Int J Clin Pharmacol Ther 2012; 50(5): 315-22.
[http://dx.doi.org/10.5414/CP201632] [PMID: 22541835]
[68]
Blouin J, Dragomir A, Fredette M, Ste-Marie LG, Fernandes JC, Perreault S. Comparison of direct health care costs related to the pharmacological treatment of osteoporosis and to the management of osteoporotic fractures among compliant and noncompliant users of alendronate and risedronate: a population-based study. Osteoporos Int 2009; 20(9): 1571-81.
[http://dx.doi.org/10.1007/s00198-008-0818-5] [PMID: 19107385]
[69]
Colombo GL, Montecucco CM. Generic vs brand originator alendronate: analysis of persistence and compliance in five Local Healthcare Units in the Lombardy Region of Italy. Clin Cases Miner Bone Metab 2013; 10(3): 195-8.
[PMID: 24554931]
[70]
Feldstein AC, Weycker D, Nichols GA, et al. Effectiveness of bisphosphonate therapy in a community setting. Bone 2009; 44(1): 153-9.
[http://dx.doi.org/10.1016/j.bone.2008.09.006] [PMID: 18926939]
[71]
Siris ES, Pasquale MK, Wang Y, Watts NB. Estimating bisphosphonate use and fracture reduction among US women aged 45 years and older, 2001-2008. J Bone Miner Res 2011; 26(1): 3-11.
[http://dx.doi.org/10.1002/jbmr.189] [PMID: 20662073]
[72]
Morley J, Moayyeri A, Ali L, et al. Persistence and compliance with osteoporosis therapies among postmenopausal women in the UK Clinical Practice Research Datalink. Osteoporos Int 2020; 31(3): 533-45.
[http://dx.doi.org/10.1007/s00198-019-05228-8] [PMID: 31758206]
[73]
Cheen MH, Kong MC, Zhang RF, Tee FM, Chandran M. Adherence to osteoporosis medications amongst Singaporean patients. Osteoporos Int 2012; 23(3): 1053-60.
[http://dx.doi.org/10.1007/s00198-011-1635-9] [PMID: 21503813]
[74]
Cheng TT, Yu SF, Hsu CY, Chen SH, Su BY, Yang TS. Differences in adherence to osteoporosis regimens: a 2-year analysis of a population treated under specific guidelines. Clin Ther 2013; 35(7): 1005-15.
[http://dx.doi.org/10.1016/j.clinthera.2013.05.019] [PMID: 23831360]
[75]
Cotté FE, Fardellone P, Mercier F, Gaudin AF, Roux C. Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis. Osteoporos Int 2010; 21(1): 145-55.
[http://dx.doi.org/10.1007/s00198-009-0930-1] [PMID: 19459025]
[76]
Curtis JR, Westfall AO, Allison JJ, Freeman A, Saag KG. Channeling and adherence with alendronate and risedronate among chronic glucocorticoid users. Osteoporos Int 2006; 17(8): 1268-74.
[http://dx.doi.org/10.1007/s00198-006-0136-8] [PMID: 16724286]
[77]
Devine J, Trice S, Finney Z, et al. A retrospective analysis of extended-interval dosing and the impact on bisphosphonate compliance in the US Military Health System. Osteoporos Int 2012; 23(4): 1415-24.
[http://dx.doi.org/10.1007/s00198-011-1729-4] [PMID: 21786005]
[78]
Dugard MN, Jones TJ, Davie MW. Uptake of treatment for osteoporosis and compliance after bone density measurement in the community. J Epidemiol Community Health 2010; 64(6): 518-22.
[http://dx.doi.org/10.1136/jech.2008.084558] [PMID: 19679704]
[79]
Hansen KE, Swenson ED, Baltz B, Schuna AA, Jones AN, Elliott ME. Adherence to alendronate in male veterans. Osteoporos Int 2008; 19(3): 349-56.
[http://dx.doi.org/10.1007/s00198-007-0471-4] [PMID: 17898921]
[80]
Hawley S, Javaid MK, Rubin KH, et al. Incidence and predictors of multiple fractures despite high adherence to oral bisphosphonates: a binational population-based cohort study. J Bone Miner Res 2016; 31(1): 234-44.
[http://dx.doi.org/10.1002/jbmr.2595] [PMID: 26174968]
[81]
Kamatari M, Koto S, Ozawa N, et al. Factors affecting long-term compliance of osteoporotic patients with bisphosphonate treatment and QOL assessment in actual practice: alendronate and risedronate. J Bone Miner Metab 2007; 25(5): 302-9.
[http://dx.doi.org/10.1007/s00774-007-0768-6] [PMID: 17704995]
[82]
Kertes J, Dushenat M, Vesterman JL, Lemberger J, Bregman J, Friedman N. Factors contributing to compliance with osteoporosis medication. Isr Med Assoc J 2008; 10(3): 207-13.
[PMID: 18494234]
[83]
Landfeldt E, Ström O, Robbins S, Borgström F. Adherence to treatment of primary osteoporosis and its association to fractures--the Swedish Adherence Register Analysis (SARA). Osteoporos Int 2012; 23(2): 433-43.
[http://dx.doi.org/10.1007/s00198-011-1549-6] [PMID: 21286686]
[84]
McCombs JS, Thiebaud P, McLaughlin-Miley C, Shi J. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 2004; 48(3): 271-87.
[http://dx.doi.org/10.1016/j.maturitas.2004.02.005] [PMID: 15207894]
[85]
Modi A, Tang J, Sen S, Díez-Pérez A. Osteoporotic fracture rate among women with at least 1 year of adherence to osteoporosis treatment. Curr Med Res Opin 2015; 31(4): 767-77.
[http://dx.doi.org/10.1185/03007995.2015.1016606] [PMID: 25708648]
[86]
Papaioannou A, Ioannidis G, Adachi JD, et al. Adherence to bisphosphonates and hormone replacement therapy in a tertiary care setting of patients in the CANDOO database. Osteoporos Int 2003; 14(10): 808-13.
[http://dx.doi.org/10.1007/s00198-003-1431-2] [PMID: 14523610]
[87]
Rabenda V, Mertens R, Fabri V, et al. Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int 2008; 19(6): 811-8.
[http://dx.doi.org/10.1007/s00198-007-0506-x] [PMID: 17999022]
[88]
Richards JS, Cannon GW, Hayden CL, et al. Adherence with bisphosphonate therapy in US veterans with rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012; 64(12): 1864-70.
[http://dx.doi.org/10.1002/acr.21777] [PMID: 22740421]
[89]
Sampalis JS, Adachi JD, Rampakakis E, Vaillancourt J, Karellis A, Kindundu C. Long-term impact of adherence to oral bisphosphonates on osteoporotic fracture incidence. J Bone Miner Res 2012; 27(1): 202-10.
[http://dx.doi.org/10.1002/jbmr.533] [PMID: 21976304]
[90]
Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006; 81(8): 1013-22.
[http://dx.doi.org/10.4065/81.8.1013] [PMID: 16901023]
[91]
Weycker D, Macarios D, Edelsberg J, Oster G. Compliance with drug therapy for postmenopausal osteoporosis. Osteoporos Int 2006; 17(11): 1645-52.
[http://dx.doi.org/10.1007/s00198-006-0179-x] [PMID: 16862397]
[92]
Briesacher BA, Andrade SE, Yood RA, Kahler KH. Consequences of poor compliance with bisphosphonates. Bone 2007; 41(5): 882-7.
[http://dx.doi.org/10.1016/j.bone.2007.07.009] [PMID: 17707710]
[93]
Briesacher BA, Andrade SE, Harrold LR, Fouayzi H, Yood RA. Adoption of once-monthly oral bisphosphonates and the impact on adherence. Am J Med 2010; 123(3): 275-80.
[http://dx.doi.org/10.1016/j.amjmed.2009.05.017] [PMID: 20193837]
[94]
Cadarette SM, Solomon DH, Katz JN, Patrick AR, Brookhart MA. Adherence to osteoporosis drugs and fracture prevention: no evidence of healthy adherer bias in a frail cohort of seniors. Osteoporos Int 2011; 22(3): 943-54.
[http://dx.doi.org/10.1007/s00198-010-1309-z] [PMID: 20532481]
[95]
Copher R, Buzinec P, Zarotsky V, Kazis L, Iqbal SU, Macarios D. Physician perception of patient adherence compared to patient adherence of osteoporosis medications from pharmacy claims. Curr Med Res Opin 2010; 26(4): 777-85.
[http://dx.doi.org/10.1185/03007990903579171] [PMID: 20095797]
[96]
Curtis JR, Xi J, Westfall AO, et al. Improving the prediction of medication compliance: the example of bisphosphonates for osteoporosis. Med Care 2009; 47(3): 334-41.
[http://dx.doi.org/10.1097/MLR.0b013e31818afa1c] [PMID: 19194337]
[97]
Devold HM, Furu K, Skurtveit S, Tverdal A, Falch JA, Sogaard AJ. Influence of socioeconomic factors on the adherence of alendronate treatment in incident users in Norway. Pharmacoepidemiol Drug Saf 2012; 21(3): 297-304.
[http://dx.doi.org/10.1002/pds.2344] [PMID: 22237942]
[98]
Lin TC, Yang CY, Yang YH, Lin SJ. Alendronate adherence and its impact on hip-fracture risk in patients with established osteoporosis in Taiwan. Clin Pharmacol Ther 2011; 90(1): 109-16.
[http://dx.doi.org/10.1038/clpt.2011.62] [PMID: 21525868]
[99]
Martin KE, Yu J, Campbell HE, Abarca J, White TJ. Analysis of the comparative effectiveness of 3 oral bisphosphonates in a large managed care organization: adherence, fracture rates, and all-cause cost. J Manag Care Pharm 2011; 17(8): 596-609.
[http://dx.doi.org/10.18553/jmcp.2011.17.8.596] [PMID: 21942301]
[100]
Modi A, Sajjan S, Michael Lewiecki E, Harris ST, Papadopoulos Weaver J. Relationship between gastrointestinal events and compliance with osteoporosis therapy: an administrative claims analysis of the US managed care population. Clin Ther 2016; 38(5): 1074-80.
[http://dx.doi.org/10.1016/j.clinthera.2016.03.027] [PMID: 27112533]
[101]
Olsen KR, Hansen C, Abrahamsen B. Association between refill compliance to oral bisphosphonate treatment, incident fractures, and health care costs--an analysis using national health databases. Osteoporos Int 2013; 24(10): 2639-47.
[http://dx.doi.org/10.1007/s00198-013-2365-y] [PMID: 23604250]
[102]
Penning-van Beest FJ, Erkens JA, Olson M, Herings RM, Herings RM. Loss of treatment benefit due to low compliance with bisphosphonate therapy. Osteoporos Int 2008; 19(4): 511-7.
[http://dx.doi.org/10.1007/s00198-007-0466-1] [PMID: 17874028]
[103]
Recker RR, Gallagher R, MacCosbe PE. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 2005; 80(7): 856-61.
[http://dx.doi.org/10.4065/80.7.856] [PMID: 16007889]
[104]
Tafaro L, Nati G, Leoni E, et al. Adherence to anti-osteoporotic therapies: role and determinants of “spot therapy”. Osteoporos Int 2013; 24(8): 2319-23.
[http://dx.doi.org/10.1007/s00198-013-2283-z] [PMID: 23404614]
[105]
Weycker D, Lamerato L, Schooley S, et al. Adherence with bisphosphonate therapy and change in bone mineral density among women with osteoporosis or osteopenia in clinical practice. Osteoporos Int 2013; 24(4): 1483-9.
[http://dx.doi.org/10.1007/s00198-012-2108-5] [PMID: 22903292]
[106]
Yood RA, Emani S, Reed JI, Lewis BE, Charpentier M, Lydick E. Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int 2003; 14(12): 965-8.
[http://dx.doi.org/10.1007/s00198-003-1502-4] [PMID: 14504697]
[107]
Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 2004; 15(12): 1003-8.
[http://dx.doi.org/10.1007/s00198-004-1652-z] [PMID: 15167989]
[108]
Solomon DH, Avorn J, Katz JN, et al. Compliance with osteoporosis medications. Arch Intern Med 2005; 165(20): 2414-9.
[http://dx.doi.org/10.1001/archinte.165.20.2414] [PMID: 16287772]
[109]
Huybrechts KF, Ishak KJ, Caro JJ. Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 2006; 38(6): 922-8.
[http://dx.doi.org/10.1016/j.bone.2005.10.022] [PMID: 16330270]
[110]
Emkey RD, Ettinger M. Improving compliance and persistence with bisphosphonate therapy for osteoporosis. Am J Med 2006; 119(4)(Suppl. 1): S18-24.
[http://dx.doi.org/10.1016/j.amjmed.2005.12.019] [PMID: 16563937]

Rights & Permissions Print Cite
Article Metrics
21
1
© 2024 Bentham Science Publishers | Privacy Policy